Skip to main content
OpenTrials
Completed

NCT Number: NCT06668168

The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable.

Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet.

Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC & NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors.

Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans.

The investigators will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. The investigators will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Bath

Bath, BA2 7AY, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index: 25-45 kg/m2
  • Waist circumference >93.9 (males) or >79.9 (females)

Exclusion criteria

  • Glucose or lipid lowering medication
  • Diagnosis of cardiovascular disease, renal failure, liver disease or type 2 diabetes
  • Contraindications to a ketogenic diet (e.g., pancreatitis, liver failure, disorders of fat metabolism, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyrias, or pyruvate kinase deficiency)
  • Unable to understand English language

Treatment and study plan

Ketone Monoester (KE)

Dietary Supplement

25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate].

Ketogenic diet

Behavioral

Ketogenic diet (<50 g carbohydrate per day)

Primary outcomes

  1. Plasma proteome

    Time frame: From baseline to week 4

    Plasma proteome at week 4 adjusted for baseline values

  2. Transcriptome of peripheral blood mononuclear cells

    Time frame: From baseline to week 4

    Transcriptome of peripheral blood mononuclear cells at week 4 adjusting for baseline values

  3. Transcriptome of adipose tissue

    Time frame: From baseline to week 4

    Transcriptome of subcutaneous abdominal adipose tissue at week 4 adjusting for baseline values

Secondary outcomes

  1. Apolipoprotein B concentrations

    Time frame: From baseline to week 4

    Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.

  2. Urinary albumin concentrations

    Time frame: From baseline to week 4

    Urinary albumin concentrations at week 4 adjusting for baseline values

  3. Fasting glucose concentrations

    Time frame: From baseline to week 4

    Plasma fasting glucose concentrations at week 4 adjusting for baseline values

Sponsors and collaborators

Lead sponsor

University of Bath

Other

Collaborators

  • Imperial College London
  • University of Bristol

Registry information

Acronym: KETO-GENETIC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 31, 2024
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.